[ad_1]
pharmaceutical company AstraZeneca announced that its coronavirus vaccine showed an average efficacy of 70% in protection against the virus in two study segments. The drug, developed with the University of Oxford, is currently far behind its competitors, who in recent weeks had anticipated much higher figures. The first was Pfizer, which had reported the effectiveness of the 90% then corrected to 95%. This was followed by the Modern Society announcement that their drug had been shown to protect against Coronavirus for 94.5%.
Astrazeneca efficacy concerns declared by different age groups, including seniors, along a path of experimentation that still has a good stretch of road ahead. “Today’s announcement,” said Professor vaccine at the University of Oxford, Sarah Gilbert, “gives us one step closer to the time we use vaccines to end the devastation caused by Covid-19”. .
Force points
Despite a lower efficacy rate than the recent Pfizer and Moderna advertisements have accustomed us to, the strengths Astrazeneca highlighted for its vaccine candidate are the cheaper cost than the other two and easier storage. On the second point, the advantageous consequence would also be a greater ease of distribution throughout the world.
“The simple vaccine supply chain and our nonprofit commitment to having broad, fair and timely access,” said Pascal Soriot, CEO of AstraZeneca, “means it will be affordable and available globally, providing hundreds of millions dose. ”And in this sense the British government has already ordered 100 million doses of the vaccine developed by the University of Oxford, sufficient to immunize 50 million from the people.
Read also:
[ad_2]
